ELVO

ELVO
Peeperman · Public domain · source
Name	ELVO
Specialty	Neurology

ELVO

ELVO is an acute cerebrovascular condition characterized by sudden occlusion of a major intracranial artery leading to severe focal neurological deficit. It commonly presents as an acute ischemic stroke syndrome requiring rapid identification and reperfusion, and it intersects clinical pathways involving emergency medicine, neurology, neuroradiology, and interventional cardiology. Treatment pathways link to systems and organizations that manage acute stroke care and influence outcomes across hospitals and health systems.

Definition and overview

ELVO denotes large-caliber intracranial arterial occlusion producing extensive territory ischemia in distributions of arteries such as the internal carotid artery, middle cerebral artery, anterior cerebral artery, and posterior circulation vessels including the basilar artery and vertebral artery. Clinical presentation overlaps with syndromes cataloged by stroke scales developed by organizations like the National Institutes of Health and protocols endorsed by the American Heart Association and American Stroke Association. The condition is central to randomized trials and guideline documents produced by entities such as the DAWN trial, DEFUSE 3 trial, and professional societies including the European Stroke Organisation.

Etiology and risk factors

Etiologies include in situ thromboembolism from atherosclerotic plaques of the carotid artery or vertebral artery, cardioembolism associated with arrhythmias such as atrial fibrillation, and artery-to-artery embolism related to unstable plaque in the aortic arch. Other causes comprise cervical artery dissections seen in contexts involving connective tissue disorders like Ehlers–Danlos syndrome and inflammatory vasculopathies including giant cell arteritis. Iatrogenic sources relate to endovascular procedures performed by specialists at centers such as the Mayo Clinic or Cleveland Clinic, while hypercoagulable states associated with malignancies like pancreatic cancer or hematologic disorders contribute risk. Demographic and comorbid contributors include advanced age, prior myocardial infarction, uncontrolled hypertension linked to trials by groups like the Systolic Hypertension in the Elderly Program, hyperlipidemia treated according to guidance from the National Lipid Association, and diabetes mellitus described by the American Diabetes Association.

Diagnosis and imaging

Rapid diagnosis relies on clinical scales such as the National Institutes of Health Stroke Scale and emergency triage protocols used in systems like the Stroke Belt networks and regional stroke centers accredited by the Joint Commission. Neuroimaging modalities include noncontrast computed tomography to exclude hemorrhage, computed tomography angiography (CTA) to visualize occlusion of vessels like the middle cerebral artery and internal carotid artery, and perfusion imaging with CT or magnetic resonance imaging using diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) as utilized in studies from the Stroke Imaging Research (STIR) consortium. Digital subtraction angiography (DSA) performed in interventional suites at centers influenced by pioneers at institutions such as Massachusetts General Hospital remains the gold standard for vessel lumen assessment and mechanical thrombectomy planning.

Treatment and management

Acute reperfusion therapy comprises intravenous thrombolysis with agents discussed in trials sponsored by the National Institute of Neurological Disorders and Stroke and endovascular mechanical thrombectomy performed with devices developed by companies collaborating with academic centers like Stanford University and Johns Hopkins Hospital. Systems of care emphasize drip-and-ship and mothership models coordinated by emergency medical services such as EMSA and regional networks modeled after programs in Los Angeles County and London. Peri-procedural management involves neurocritical care units following protocols from the Society of Critical Care Medicine and antithrombotic strategies aligned with guidance from the European Society of Cardiology or the American College of Cardiology when cardioembolic sources such as prosthetic heart valves or infective endocarditis are relevant. Secondary prevention incorporates carotid revascularization techniques referenced in trials from the North American Symptomatic Carotid Endarterectomy Trial and anticoagulation strategies informed by studies in atrial fibrillation cohorts.

Outcomes and prognosis

Functional outcomes after ELVO are strongly time-dependent, with better independence metrics reported in trials such as MR CLEAN and ESCAPE when reperfusion is achieved rapidly. Prognostic determinants include initial infarct core volume measured with perfusion maps in trials like DAWN, collateral circulation quality described in literature from the ASPECTS scoring framework, patient age, baseline comorbidities including prior stroke and coronary artery disease, and reperfusion success measured by the modified Thrombolysis in Cerebral Infarction (mTICI) scale used in interventional series at institutions like Mount Sinai Health System. Long-term outcomes engage rehabilitation services exemplified by programs at the Kessler Foundation and affect measures such as return to work and healthcare utilization tracked in registries like the Get With The Guidelines–Stroke program.

Epidemiology and public health impact

ELVO accounts for a disproportionate share of severe ischemic strokes and stroke-related disability in population studies conducted by agencies such as the Centers for Disease Control and Prevention and the World Health Organization. Incidence varies with demographics and regional stroke systems of care, with higher case-fatality and dependency rates reported in underserved regions referenced in global burden analyses by the Global Burden of Disease Study. Implementation of organized stroke networks, telestroke programs developed by institutions like Duke University Health System, and public health campaigns modeled after initiatives from the American Heart Association influence time-to-treatment metrics and population-level outcomes. Health economics assessments conducted by researchers at academic centers including Harvard Medical School evaluate cost-effectiveness of thrombectomy and system reorganization for ELVO management.

Category:Stroke